How does an investor profit if a company has the best technology in the world, but can't deliver market-beating returns? That's probably a harsh intro for Hologic (Nasdaq:HOLX) today, but the fact remains that the company has to demonstrate that it can drive tomosynthesis adoption and solid growth in diagnostics for this stock to really work over the coming years. That puts the shares in a challenging place for investors; bulls can likely see a lot of value here, while bears will point to the high debt and oncoming competition and likely conclude that the shares are best avoided for now.

Investopedia Broker Guide: Enhance your trading with the tools from today's top online brokers

A Decent Close to the Year
Due to an extra week in the quarter, a purchase accounting adjustment and the impact of the Gen-Probe acquisition, this was a messy quarter for Hologic investors. The good news is that, on balance, this a solid quarter with most of the key items ahead of expectations. Institutional and individual investors can effectively use earnings to gain a good hold on a company.

Revenue rose about 29%, including the purchase adjustment. On an organic basis, revenue rose about 7 to 8% (depending upon whether you factor in the extra week), with breast health revenue up about 6%, legacy diagnostics up 10% and gyn/surgery up 17% (ex-Adiana) on strong MyoSure performance. These results were all modestly better than expected, though it looks like Gen-Probe's growth was a little less impressive than previously forecast.

On the profit side, Hologic likewise did pretty well. Gross margin (adjusted) was up about a half-point from last year, but a little shy of most sell-side estimates. Operating income (also adjusted) rose about 28%, with a slightly better-than-expected operating margin.

Tomo Tomorrow?
Hologic continues to see customers its new(ish) tomosynthesis platform in the breast health business, but the pace continues to be slower than the original pre-launch hopes of most analysts. The issue is not that the system has disappointed clinicians or administrators, nor that General Electric (NYSE:GE), Siemens (NYSE:SI) or Philips (NYSE:PHG) are capturing share. Rather, the issue is that reimbursement has been slow to come and hospital administrators have to rational budget dollars across other options like Intuitive Surgical's (Nasdaq:ISRG) robots and Varian's (NYSE:VAR) radiation oncology systems, both of which have better-established reimbursement today.

In time, this situation should improve. The long-awaited Oslo dataset should be published next year, and that should open the door to better reimbursement. That said, the ongoing sluggishness and budget consciousness in Europe shouldn't be ignored, particularly as it may well shrink Hologic's time-to-market advantage over its rivals.

Navigating the Crosswinds in Diagnostics
Hologic's large diagnostics business is likewise facing some challenging crosswinds. On the negative side, the core ThinPrep business is being challenged by recommendations for larger intervals between tests. At the same time, companies like Cepheid (Nasdaq:CPHD), Qiagen (Nasdaq:QGEN) and Becton Dickinson (NYSE:BDX) are all trying to build their own diagnostics businesses and there are only so many dollars and patients to go around.

On the positive side, Cervista is growing well and HPV testing is still under-penetrated (and Qiagen should be a beatable opponent). Likewise, while core ThinPrep testing volume may be under pressure in the developed world, emerging market demand, while risky, should help offset this to some extent. Last and not least, Gen-Probe should improve Hologic's overall diagnostics platform, particularly enhancing efforts like molecular diagnostics and automated platforms.

The Bottom Line
Hologic had to use a lot more high-cost financing to do the Gen-Probe deal than originally hoped, and that carries a real cost. On the flip side, we're still talking about a business that has long generated good free cash flow, and that should add a deleveraging kicker to the Hologic bull thesis.

As I said in the intro, the fair value calculation on Hologic is a little more complicated than usual right now. Investors who believe that tomosynthesis adoption is a "when, not if" proposition and that Hologic will be the leading platform, as well as those who believe that Gen-Probe will strengthen Hologic's hand in diagnostics, will see these shares as offering pretty good long-term returns from these levels. I'm inclined to fly the flag for the bull camp when it comes to Hologic, but competition and leverage up the risks here and this is definitely not a stock for those looking for a conservative health care investment.

At the time of writing, Stephen D. Simpson did not own any shares in any company mentioned in this article.

Related Articles
  1. Stock Analysis

    Allstate: How Being Boring Earns it Billions (ALL)

    A summary of what Allstate Insurance sells and whom it sells it to including recent mergers and acquisitions that have helped boost its bottom line.
  2. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  3. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  4. Economics

    Is Wall Street Living in Denial?

    Will remaining calm and staying long present significant risks to your investment health?
  5. Stock Analysis

    When Will Dick's Sporting Goods Bounce Back? (DKS)

    Is DKS a bargain here?
  6. Investing News

    How AT&T Evolved into a Mobile Phone Giant

    A third of Americans use an AT&T mobile phone. How did it evolve from a state-sponsored monopoly, though antitrust and a technological revolution?
  7. Stock Analysis

    Home Depot: Can its Shares Continue Climbing?

    Home Depot has outperformed the market by a wide margin in the last 12 months. Is this sustainable?
  8. Stock Analysis

    Yelp: Can it Regain its Losses in 2016? (YELP)

    Yelp investors have had reason to be happy recently. Will the good spirits last?
  9. Stock Analysis

    Is Walmart's Rally Sustainable? (WMT)

    Walmart is enjoying a short-term rally. Is it sustainable? Is Amazon still a better bet?
  10. Stock Analysis

    GoPro's Stock: Can it Fall Much Further? (GPRO)

    As a company that primarily sells discretionary products, GoPro and its potential falls right in line with consumer trends. Is that good or bad?
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center